Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus

Background: Bevacizumab and temsirolimus are active agents in gynecologic tumors. Temsirolimus attenuates upregulation of HIF-1α levels, a resistance mechanism for antiangiogenics, and targets the PI3-kinase/AKT/mTOR axis, commonly aberrant in these tumors Patients and Methods: We analyzed safety an...

Full description

Saved in:
Bibliographic Details
Main Authors: Piha-Paul, Sarina A., Wheler, Jennifer J., Fu, Siqing, Levenback, Charles, Lu, Karen, Falchook, Gerald S., Naing, Aung, Hong, David S., Tsimberidou, Apostolia M., Kurzrock, Razelle
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2014
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4039109/
https://ncbi.nlm.nih.gov/pubmed/24742900
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items